Lundbeck’s environmental footprint is dominated by the use of raw materials and resources (water and energy), the generation of waste, wastewater and airborne emissions. We also consider the disposal of medicinal residues from patients as part of our environmental footprint. We continuously map and evaluate our environmental footprint in order to be able to reduce our environmental impacts.

Lundbeck has a Health Safety & Environment (HSE) strategy which helps us ensure a prioritized and coordinated effort in reducing our environmental footprint. All our HSE activities are coordinated via our ISO 14001-certified HSE management system that covers research, development and manufacturing sites globally, as well as our headquarter functions.

For a number of years, the strategy and the HSE system has yielded a number of significant results. It has enabled us to safely manufacture pharmaceuticals while using less energy and emitting less CO₂ than ever before.

Environmental considerations are integrated already when developing new products and processes. We seek to optimize our synthesis to have high process yield and to use the least harmful substances and apply processes that pose the lowest risk to the environment. In the production phase, regeneration of solvents is a way to gain both environmental and financial benefits. Our target in 2019 is to regenerate 75% of the top 10 solvents e.g. by using a fractionating column, we are able to regenerate solvents effectively. As a result, post-purification solvents can be reused in all processes, over and over again. This leads to reduced sourcing of new solvents.

Based on an Environmental Risk Assessment Lundbeck also monitors the environmental effects of the active pharmaceutical ingredients in our new medicinal products. The knowledge which is gained is applied to the design and manufacturing process resulting in the least possible environmental impact.

Our future key challenges and opportunities with regard to the environment include:

- Contributing to the development of environmentally sound technologies e.g. implementation of continuous processes in the production.
- Systematically performing risk assessments prior to new facilities, buildings and processes are established.
- Continuously minimizing the use of raw materials and reducing air emissions and generation of waste by recovery of solvents, process optimisations and circular economy.
- Supporting initiatives to improve data quality and to minimize the presence and effects of pharmaceuticals in the environment. See our Position on Biodiversity.
- Developing and maintaining the environmental principles in the Lundbeck Supplier Standards.
- Continuously reducing our CO₂ emissions. See our Position on Climate Change.
- Continuously reducing our water consumption. See our Position on Water.
- Participating in the Environmental Protection Agency task forces, aiming to develop Best Available Technology regulation.
- Keeping an open and honest dialogue with our stakeholders e.g. by reporting our HSE performance to UN Global Compact, FTSE4GOOD and Carbon Disclosure Project (CDP).

In our UN Global Compact Progress report on www.Lundbeck.com you can read more about our activities and performance.